Clinical Trial: Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Multicenter, Single-blind, Within-subject, Placebo-controlled Proof of Concept Study to Assess the Effect of Single Oral Doses of BGG492 on the Photoparoxysmal EEG Response in Patients With Photosen

Brief Summary: This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: Outcome Measure: Photoparoxysmal response (PPR) and standardized photoparoxysmal response (SPR) determined by EEG on all treatment days. [ Time Frame: Days 1, 2 and 3 ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Outcome Measure: Safety and tolerability of BGG492 in patients with photosensitive epilepsy [ Time Frame: From Day 1 until Day 33 after treatment start. ]

Original Secondary Outcome: Same as current

Information By: Novartis

Dates:
Date Received: October 31, 2008
Date Started: October 2008
Date Completion:
Last Updated: September 21, 2016
Last Verified: September 2016